IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program
2007 NOV 19 -- IDM Pharma, Inc. (NASDAQ:IDMI) announced the presentation of data from a compassionate use program evaluating mifamurtide (L-MTP-PE) in patients with lung metastases as a result of the progression of osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The data show that L-MTP-PE in combination with other therapies is safe, well-tolerated and exhibited signs of disease control. "These results are encouraging as there is a significant unmet treatment need for patients with osteosarcoma," said Dr. Peter Anderson, professor of pediatrics, The University of Texas M.D. Anderson Cancer Center in Houston. "The safety and tolerability as well as signal of disease control associated with L-MTP-PE treatment in combination with other agents is promising as we continue to investigate therapies to control lung metastases as a result of the progression of osteosarcoma." The data were presented during a poster presentation at the 39th Congress of International Society of Pediatric Oncology (SIOP) today in Mumbai, India. Keywords: Bone Cancer, Bone Tumors, Hematology, IDM Pharma, Oncology, Pediatric, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Therapy, Treatment, IDM Pharma Inc. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
